SEMA4D and juvenile Huntington disease: Clinical evaluation of the safety and efficacy of pepinemab (VX15/2503), a humanized anti-SEMA4D monoclonal antibody, has been initiated, including a completed Phase I trial in patients with multiple sclerosis (NCT01764737) [63], a Phase II trial in Huntington’s disease (NCT02481674) that is complete and will be reported elsewhere [64], and an ongoing Phase I/II study of pepinemab in Alzheimer’s disease (NCT04381468).